Lupus & antiphospholipid syndrome
The additional role of anti-nucleosome antibodies in the prediction of renal damage in systemic lupus erythematosus based on CSTAR (XXV)
Authors' conclusion
Besides anti-dsDNA antibodies, anti-nucleosome antibodies can also provide information about organ damage accrual during follow-up.
Study context
- Population
- Systemic Lupus Erythematosus (SLE) patients from the Chinese SLE Treatment and Research group (CSTAR) registry with full follow-up datawith full follow-up data
- Participants
- 2,481 patients
- Exposure
- Anti-nucleosome antibody positive vs negative SLE patients
- Anti-nucleosome antibodies positiven = 663
- Anti-dsDNA antibodies positiven = 1,668
- Outcome
- Organ damage accumulation
- Follow-up
- Mean 4.31 ± 2.60 years
Methodological detailsregistry-based (CSTAR), multivariable Cox regression
- Registry-based (CSTAR)
- Multivariable Cox regression
Main finding
As reported in the abstract
Organ damage accumulation (multivariable Cox regression)
Hazard ratio (95% CI)P value
Anti-nucleosome positive
1.30(1.09–1.54)
P < 0.001Anti-dsDNA positive
1.68(1.38–2.05)
P < 0.001- Patients developing new organ damage
- 764 (30.8%)
Observational data: associations, not effects.
Further findings
Organ damage accumulation (multivariable Cox regression) · mean follow-up 4.31 ± 2.60 years
| HR (95% CI) | P value | ||
|---|---|---|---|
| Anti-nucleosome antibodies positive | 1.30 (1.09–1.54) | P < 0.001 | |
| Anti-dsDNA antibodies positive | 1.68 (1.38–2.05) | P < 0.001 | |
| 0.512Hazard ratio (log scale) |
Renal damage, combination of the two antibodies, in overall SLE patients and in patients with LN at baseline (subgroup)
| HR (95% CI) | P value | ||
|---|---|---|---|
| Combination of the two antibodiesOverall SLE patients | 3.19 (2.49–4.10) | P < 0.001 | |
| Combination of the two antibodiesPatients with lupus nephritis at baseline | 2.86 (2.29–3.57) | P < 0.001 | |
| 0.20.5125Hazard ratio (log scale) |
| Outcome | Anti-nucleosome antibodies positive |
|---|---|
| Lupus nephritis at baseline | 50.7% |
- Lupus nephritis at baseline: comparator 36.2% (anti-nucleosome negative, not labelled in abstract); p < .001
Lupus nephritis at baseline
- Higher rate of LN with positive anti-nucleosome antibodies (50.7% vs 36.2%, p < .001)
Original publication
The additional role of anti-nucleosome antibodies in the prediction of renal damage in systemic lupus erythematosus based on CSTAR (XXV). Lupus. Published 9 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →